A Phase 2 interventional study of Tezacaftor/Ivacaftor and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 9 sites in Australia. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-23.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 38th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 10th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2016.
This study's enrollment of 41 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 82nd largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 21 in phase 2, and was the 51st registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The primary purpose of study is to evaluate the treatment effect of tezacaftor in combination with ivacaftor (TEZ/IVA) on chest imaging endpoints using low-dose computed tomography (LDCT) at Week 72, and to evaluate the safety of TEZ/IVA through Week 72.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
Drug: Tezacaftor/Ivacaftor · Drug: Ivacaftor
Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
Drug: Placebo
Drug pages: Tezacaftor · Ivacaftor
TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
Also known as: TEZ/IVA; VX-661/VX-770
IVA 150 mg tablet.
Also known as: VX-770; IVA
Placebo matched to TEZ/IVA fixed-dose combination tablet.
Placebo matched to IVA tablet.
Absolute Change in Total Brody/CF-CT Score
The exploratory Brody/CF-CT score semi-quantitatively scores the degree of structural lung disease as shown on CT in participants with CF. The score ranges from a minimum of 0 to a maximum of 219 with higher scores indicating more severe structural lung disease.
Time frame: From Baseline at Week 72
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 76
| Milestone | TEZ/IVA | Placebo |
|---|---|---|
| Started | 20 | 21 |
| Completed | 20 | 20 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 1 |
The exploratory Brody/CF-CT score semi-quantitatively scores the degree of structural lung disease as shown on CT in participants with CF. The score ranges from a minimum of 0 to a maximum of 219 with higher scores indicating more severe structural lung disease.
| scores on a scale | TEZ/IVA | Placebo |
|---|---|---|
| Absolute Change in Total Brody/CF-CT Score | 0.90 ± 2.09 | 2.38 ± 2.07 |
| Participants | TEZ/IVA | Placebo |
|---|---|---|
| Participants with AEs | 20 | 21 |
| Participants with SAEs | 8 | 13 |
Collected over Day 1 up to Week 76. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TEZ/IVA | 0/20 (0%) | 8/20 (40%) | 19/20 (95%) |
| Placebo | 0/21 (0%) | 13/21 (61.9%) | 20/21 (95.2%) |
| Event | TEZ/IVA | Placebo |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 5/20 | 6/21 |
| Lung infection pseudomonalInfections and infestations | 2/20 | 0/21 |
| Atrioventricular block first degreeCardiac disorders | 1/20 | 0/21 |
| Abdominal pain upperGastrointestinal disorders | 1/20 | 0/21 |
| Testicular torsionReproductive system and breast disorders | 1/20 | 0/21 |
| Atypical mycobacterial lower respiratory tract infectionInfections and infestations | 0/20 | 1/21 |
| GastroenteritisInfections and infestations | 0/20 | 1/21 |
| Abdominal painGastrointestinal disorders | 0/20 | 1/21 |
| VomitingGastrointestinal disorders | 0/20 | 1/21 |
| Hepatic cirrhosisHepatobiliary disorders | 0/20 | 1/21 |
| Event | TEZ/IVA | Placebo |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 5/20 | 9/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/20 | 9/21 |
| Bacterial test positiveInvestigations | 0/20 | 5/21 |
| Upper respiratory tract infectionInfections and infestations | 4/20 | 2/21 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 4/20 | 2/21 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 4/20 | 4/21 |
| HeadacheNervous system disorders | 1/20 | 4/21 |
| NauseaGastrointestinal disorders | 0/20 | 4/21 |
| Lower respiratory tract infection bacterialInfections and infestations | 3/20 | 2/21 |
| NasopharyngitisInfections and infestations | 3/20 | 1/21 |
| Age, Continuous(years) | TEZ/IVA | Placebo | Total |
|---|---|---|---|
| Mean | 20.4 ± 7.5 | 20.1 ± 9.3 | 20.2 ± 8.4 |
| Sex: Female, Male(Participants) | TEZ/IVA | Placebo | Total |
|---|---|---|---|
| Female | 11 | 10 | 21 |
| Male | 9 | 11 | 20 |
| Ethnicity (NIH/OMB)(Participants) | TEZ/IVA | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 20 | 21 | 41 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TEZ/IVA | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 20 | 21 | 41 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Total Brody/Cystic Fibrosis - Computed Tomography (CF-CT) Score(scores on a scale) | TEZ/IVA | Placebo | Total |
|---|---|---|---|
| Mean | 38.29 ± 22.91 | 43.68 ± 33.96 | 40.98 ± 28.72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Jul 2018, 22 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 22 months is above that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →